Peptide receptor imaging in neuroendocrine tumors: comparison between diagnostic scintigraphy and post-therapy whole-body scan

A potentially misleading finding at somatostatin receptor scintigraphy: Focal pulmonary areas of intense accumulation without computed tomography-detectable lung lesions

(2014) F. Minutoli et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Is Detection of Additional Lesions in Post–Peptide Receptor Radionuclide Therapy Scans With Respect to Diagnostic Imaging Only Due to Different Affinity of Ligands?

(2012) Fabio Minutoli et al.   CLINICAL NUCLEAR MEDICINE

I-131 MIBG post-therapy scan is more sensitive than I-123 MIBG pretherapy scan in the evaluation of metastatic neuroblastoma

(2012) Jigang Yang et al.   NUCLEAR MEDICINE COMMUNICATIONS

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours

(2011) Jaap J M Teunissen et al.   ENDOCRINE-RELATED CANCER

‘Reverse discordance’ between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan

(2011) Sandip Basu et al.   NUCLEAR MEDICINE COMMUNICATIONS

Additional Lesions Detected in Therapeutic Scans with 177Lu-DOTATATE Reflect Higher Affinity of 177Lu-DOTATATE for Somatostatin Receptors

(2011) Siroos Mirzaei et al.   ONCOLOGY

111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging

(2010) Emilio Bombardieri et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Comparisons of I-123 diagnostic and I-131 post-treatment scans for detecting residual thyroid tissue and metastases of differentiated thyroid cancer

(2009) Shingo Iwano et al.   ANNALS OF NUCLEAR MEDICINE

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

(2009) Dik J. Kwekkeboom et al.   NEUROENDOCRINOLOGY

Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours

(2008) P. Castaldi et al.   Radiologia Medica